NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024. Oppenheimer 34th Annual Healthcare Life Sciences Conference Format: Presentation and one-on-one investor meetings ...

公司介绍 - Corbus Pharmaceuticals Holdings, Inc.宣布首席执行官Yuval Cohen将在Oppenheimer第34届年度医疗保健生命科学会议上提供公司更新[1] - Corbus Pharmaceuticals Holdings, Inc.是一家致力于帮助人们战胜严重疾病的精准肿瘤学公司，总部位于马萨诸塞州Norwood[3] - 公司在新闻稿中提到了未来展望性陈述，包括与公司重组、试验结果、产品开发、临床和监管时间表、市场机会等相关的内容[4]

Key Points Corbus Pharmaceuticals has surged over 300% year-to-date after releasing promising data on January 26 from its Phase 1 trial on CRB-701. Oppenheimer's target raise to $51, alongside a significant insider purchase, signals optimism for Corbus Pharmaceuticals. Recent insider purchasing of over $9 million indicates strong confidence in Corbus Pharmaceuticals' future. 5 stocks we like better than Corbus Pharmaceuticals Shares of Corbus Pharmaceuticals NASDAQ: CRBP have already experienced a meteoric ...

公开发行情况 - Corbus Pharmaceuticals Holdings, Inc.宣布完成了其公开发行的497,3750股普通股，包括根据承销商行使的购买额外股份的权利出售的648,750股[1] - 公开发行价格为每股19.00美元，总公开发行规模约为9450万美元，扣除承销折扣和发行费用[2] - Jefferies担任本次发行的唯一簿记经理，H.C. Wainwright & Co.和Oppenheimer & Co.担任本次发行的首席经理[2] 公司背景介绍 - Corbus Pharmaceuticals Holdings, Inc.是一家总部位于马萨诸塞州诺伍德的精准肿瘤学公司，致力于通过将创新的科学方法引入已知的生物途径来帮助人们战胜严重疾病[5] - 公司的产品线包括CRB-701、CRB-601和CRB-913等产品[5] 前瞻性声明 - 公司发表的前瞻性声明中指出，实际结果可能与前瞻性声明中所示结果有所不同，存在市场条件和公司业务财务等方面的风险和不确定性[6] - 投资者被告诫不要过分依赖这些前瞻性声明，公司将不断更新前瞻性声明以反映事件或情况的变化[7]

公开发行计划 - Corbus Pharmaceuticals Holdings, Inc.计划通过公开发行股票或预先融资权证的方式筹集资金[1] 簿记管理人 - Jefferies将担任本次发行的唯一簿记管理人[2] 产品线介绍 - Corbus的产品线包括CRB-701、CRB-601和CRB-913，致力于通过创新科学方法帮助人们战胜严重疾病[3]

Andy Roberts/OJO Images via Getty Images Topline Summary Corbus Pharmaceuticals (NASDAQ:CRBP) is a microcap biotech company focused on the development of novel therapies for the treatment of cancer. They've recently experienced a meteoric surge out of the depths on the back of a positive clinical readout, but it remains very early days for the company's overall pipeline, and cash is not sufficient to keep the ball rolling without some significant financing needed. It's best to hold off on this one for now, ...

The stock of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) closed up nearly 250% last week. The gains happened after favourable pharmaceutical news that saw the stock climb above $29. CRBP was previously trading at a meagre valuation below $7. Despite the stock trading almost 25% lower in premarket on Monday, the developments are worth attention. Corbus Pharmaceuticals is a precision oncology company seeking to help people defeat serious illnesses. The company targets very rare and serious diseases us ...

Shares of little-known Corbus Pharmaceuticals (NASDAQ:CRBP) are absolutely skyrocketing today. At the time of writing, CRBP stock is up more than 300%, as investors price in a key announcement from the company. Earlier today, Corbus announced that its next-generation antibody drug (CRB-701) showed strong safety and efficacy in a first-in-human study on its effects on cervical cancer tumors. This drug conjugate is one of three key drugs that are currently in clinical trial phases but has clearly moved up the ...

CRB-701临床试验结果 - CRB-701 (SYS6002)的Q3W进度表显示，在预测的治疗相关剂量下，ORR为43%，DCR为71%[1] - CRB-701在临床试验中表现出良好的耐受性，大多数不良事件为一级或二级，并可逆转，未观察到三级以上的不良事件[2] - CRB-701 (SYS6002)的PK数据显示，TAb、ADC和MMAE的浓度与剂量成正比，与EV相比，CRB-701的游离MMAE浓度较低[3]

s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________. Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 46-43480 ...